- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT00794326
Clinical Evaluation of Low Sodium Peritoneal Dialysis (PD) Solution on Hypertensive Patients Treated With PD (PDOne)
Multicentric, Parallel, Controlled, Randomized, Single-blind Clinical Evaluation of New Low Sodium Peritoneal Dialysis Solution on Patients With Hypertension Treated With Continuous Ambulatory or Automated Peritoneal Dialysis
Przegląd badań
Status
Warunki
Interwencja / Leczenie
Szczegółowy opis
Hypertension as well as sodium and water retention are common in end-stage renal disease patients on peritoneal dialysis and expose patients to left ventricular hypertrophy and increase cardiovascular mortality.
Moreover the poor control of dry weight and sodium/water balance results in increased morbidity. A previous low sodium study and computer simulations show that sodium removal can be improved with a low sodium fluid, which allows achieving a negative sodium balance without altering water balance.
The aim of this study is to assess whether treatment with one low sodium bag can substitute for one isotonic glucose bag every day in order to reduce the blood pressure and/or medication for hypertension, defined as the primary endpoint.
In order to evaluate the main criteria, blood pressure, a 24hours Ambulatory Blood Pressure Monitoring (ABPM) will be performed twice during the study, at Baseline and at 8 weeks of treatment, according to the EMEA guidance recommendations for anti-hypertensive treatments. In addition, the self measurement of blood pressure will be performed by patients at home during three consecutive days before each visit as well as in case of symptoms of hypotension.
The study is designed in three periods:
- Run-in period during 1 month: a reference product Gambrosol Trio 40, one bag/ day will be used by all patients. This period is dedicated to train the patient in using of study product, to stabilize the patient in the PD treatment and to randomize the patient, by performing the 24h ABPM.
- Efficacy & Safety period during 6 months: each patient will be treated with one of two product : PDsol 12 (studied product) or Gambrosol Trio 40 (reference product) during 6 months. The aim of this period is to evaluate the efficacy and long-term tolerance of new PD fluid.
- Follow-up period during 2 months: without treatment. This period is dedicated to ensure the safety of the patients after the study product treatment was stopped and to obtain the information about the reversibility of product effect.
Typ studiów
Zapisy (Oczekiwany)
Faza
- Faza 3
Kontakty i lokalizacje
Lokalizacje studiów
-
-
-
Copenhagen, Dania
- Rigshospitalet
-
-
-
-
-
Besançon, Francja, 25000
- CHU Saint-Jacques
-
Caen, Francja, 14033
- CHRU
-
Chambery, Francja
- Hospital of Chambéry
-
Colmar, Francja
- CH Colmar
-
Irigny, Francja
- Calydial Dialysis Center
-
Paris, Francja
- Bichat-Claude Bernard Hospital
-
Reims, Francja, 51726
- ARPDD
-
Strasbourg, Francja
- CHRU de Strasbourg
-
-
-
-
-
Hannover, Niemcy, 30659
- KfH-Nierenzentrum am Krankenhaus Oststadt
-
Heidelberg, Niemcy
- University Hospital of Heidelberg
-
Köln, Niemcy, 51109
- KfH-Nierenzentrum
-
Offenburg, Niemcy
- Nephrology center Offenburg
-
Passau, Niemcy, 94032
- KfH-Nierenzentrum
-
Stuttgart, Niemcy
- PHV - Nephrologisches Zentrum Stuttgart
-
Trier, Niemcy, 54292
- KfH-Nierenzentrum Krankenhaus der Barmherzigen Brüder
-
-
-
-
-
Borås, Szwecja
- Södra Älvborgsläns Hospital
-
Göteborg, Szwecja
- University Hospital of Sahlgrenska
-
Lund, Szwecja
- University Hospital of Lund
-
Malmö, Szwecja
- University Hospital of Malmö
-
Skövde, Szwecja
- Skarborgs Hospital
-
Stockholm, Szwecja, 14186
- Karolinska University Hospital
-
Trollhättan, Szwecja
- Norra Älvsborgs Hospital
-
-
-
-
-
Birmingham, Zjednoczone Królestwo, B9 5SS
- Birmingham Heartlands Hospital
-
Bristol, Zjednoczone Królestwo, BS10 5NB
- Southmead Hospital
-
London, Zjednoczone Królestwo, E1 1BB
- The Royal London Hospital
-
Shrewsbury, Zjednoczone Królestwo, SY3 8XQ
- Royal Shrewsbury Hospital
-
Stoke on Trent, Zjednoczone Królestwo, ST47LN
- University of North Staffordshire - Renal Medicine - Royal Infirmary
-
Wolverhampton, Zjednoczone Królestwo, WV10 0QP
- Wolverhampton New Cross Hospital
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Chronic renal failure
- Stable patients on PD treatment
- Treatment at the study site for at least three months
- Treated in a CAPD program with a minimum of 3 bag exchanges with 6 or 7 days per week including at least one with duration of 4-6 hours, and at least one low strength bag per day, or in an APD program with at least one daytime exchange with duration of 4-6 hours using one low strength bag
- Hypertensive patients with high blood pressure at inclusion visit (Office SBP ≥ 140 and/or DBP ≥ 90 mmHg) or hypertensive patients receiving anti hypertensive medication including diuretics, disregarded blood pressure values
- Patients aged 18 years or more
- Written consent to participate in the study (informed consent)
- Able to use a three-compartment bag
- Life expectancy and expected technical survival ≥ 9 months
Exclusion Criteria:
- Low blood pressure (Office sitting SBP ≤ 120 mmHg and confirmed by ABPM < or = to 105 mean 24h SBP)
- Orthostatic hypotension defined as Systolic OBP with a drop of > 20mmHg and symptomatic after standing for at least 1 minute
- Natremia < 130 mmol/l, after two consecutive measurements
- Chronic arrhythmia
- Pregnancy or lactation
- Participation in other studies during the study period which may affect the outcome of the present study
- Peritonitis within one month prior to the study start
- Exit site and /or tunnel infection
- Patients unable to tolerate 2 L bag exchanges
- Patients on non-compatible PD system
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Pojedynczy
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
---|---|
Eksperymentalny: PDsol 12
Treatment with a peritoneal dialysis solution containing a low concentration of sodium.
|
Treatment with one bag per day during 6 months
|
Aktywny komparator: Gambrosol trio 40
Treatment with the peritoneal dialysis solution Gambrosol trio 40 isotonic bag (1.5%)
|
Treatment with one bag per day during 6 months
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Ramy czasowe |
---|---|
The primary criterion is the ambulatory 24 h mean systolic blood pressure measurement and drug doses management after 2 months of treatment compared to Baseline.
Ramy czasowe: At the beginning and after 8 weeks of treatment
|
At the beginning and after 8 weeks of treatment
|
Miary wyników drugorzędnych
Miara wyniku |
Ramy czasowe |
---|---|
Measurement of Residual Renal Function
Ramy czasowe: At the beginning, at two and six months of treatment
|
At the beginning, at two and six months of treatment
|
Follow-up of frequency of hyponatremia, of AE and SAE
Ramy czasowe: During whole period of the study
|
During whole period of the study
|
Assessment of changes in sodium removal
Ramy czasowe: At the beginning and at two months of treatment
|
At the beginning and at two months of treatment
|
Assessment of decrease in total body water (extra and intra cellular water)and of the body weigh changes
Ramy czasowe: At the beginning, at two and at six months of treatment
|
At the beginning, at two and at six months of treatment
|
Measurement of 24hours peritoneal clearance
Ramy czasowe: At the beginning and at 2 months of treatment
|
At the beginning and at 2 months of treatment
|
Office systolic and diastolic blood pressure measurement at month 2 and 6 versus T0
Ramy czasowe: At the beginning, at two and six months of treatment
|
At the beginning, at two and six months of treatment
|
Office systolic and diastolic blood pressure measurement during follow up period
Ramy czasowe: End of treatment, follow-up period
|
End of treatment, follow-up period
|
Współpracownicy i badacze
Śledczy
- Krzesło do nauki: Simon Davies, Prof, University Hospital of North Staffordshire, Stoke-on-Trent, UK
- Krzesło do nauki: Bengt Rippe, Prof, Lund University
- Krzesło do nauki: Börje Haraldsson, Prof, Sahlgrenska University Hospital, Göteborg, Sweden
- Krzesło do nauki: François Vrtovsnik, Prof, Bichat -Claude Bernard Hospital, Paris, France
- Krzesło do nauki: Vedat Schwenger, Dr, Universitätsklinik University Hospital, Heidelberg, Germany
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów
Zakończenie podstawowe (Rzeczywisty)
Ukończenie studiów (Rzeczywisty)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Oszacować)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Oszacować)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- 1449 (Inny identyfikator: CSL Behring)
- EudraCT 2007-005365-35
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .